MoonLake climbs after report of Merck buyout talks
View all comments(0)
Shares of Swiss biotech MoonLake Immunotherapeutics MLTX.O rise 14.8% to $47.25
Merck MRK.N has held talks to buy MLTX for more than $3 billion, the Financial Times reported on Monday, citing people familiar with the matter
Merck had submitted a nonbinding offer for MoonLake earlier this year - report
MRK's initial approach was rejected, but discussions can potentially resume, the report says
Including session moves, MLTX down 12.6% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.